The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.

Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development. Onco Targets Ther (2014) 0.86

MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. Comput Struct Biotechnol J (2016) 0.85

Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther (2015) 0.80

Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies? Stem Cell Investig (2016) 0.77

Immunohistochemical analysis of PDK1 expression in breast cancer. Diagn Pathol (2014) 0.77

Tetraspanin CD82 Regulates the Spatiotemporal Dynamics of PKCα in Acute Myeloid Leukemia. Sci Rep (2016) 0.76

Informative gene selection and the direct classification of tumors based on relative simplicity. BMC Bioinformatics (2016) 0.75

The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget (2016) 0.75

MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1. J Cell Mol Med (2016) 0.75

Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination. Cancers (Basel) (2017) 0.75

Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer (2007) 5.71

PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol (2004) 5.10

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71

Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J (2003) 4.65

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol (2006) 4.47

The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol (2000) 4.24

mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med (2007) 3.66

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96

Essential role of PDK1 in regulating cell size and development in mice. EMBO J (2002) 2.93

Cellular signaling: pivoting around PDK-1. Cell (2000) 2.86

Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell (2013) 2.64

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia (2006) 2.28

PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol (2008) 2.27

Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J (2011) 2.10

Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00

Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem (2005) 1.92

Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett (2000) 1.73

Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J (2009) 1.68

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer (2005) 1.48

Clonal evolution of acute leukemia genomes. Oncogene (2012) 1.46

Small-molecule inhibitors of PDK1. ChemMedChem (2008) 1.43

Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem (2006) 1.42

Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. Trends Biochem Sci (2004) 1.41

Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res (2002) 1.40

Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res (2008) 1.32

Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res (2006) 1.25

BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res (2000) 1.22

Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol (2000) 1.22

PDK1: the major transducer of PI 3-kinase actions. Curr Top Microbiol Immunol (2010) 1.12

Acute myeloid leukemia in the elderly. Semin Oncol (2008) 1.10

Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res (2003) 1.09

Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem (2007) 1.08

Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem (2011) 1.04

Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells. Exp Cell Res (2008) 1.04

A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am J Pathol (2009) 0.98

The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood (2007) 0.97

Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood (2002) 0.93

PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression. J Biol Chem (2008) 0.92

An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours. Br J Cancer (2008) 0.91

Three-amino-acid-loop-extension homeodomain factor Meis3 regulates cell survival via PDK1. Proc Natl Acad Sci U S A (2010) 0.86

Proliferative and antiapoptotic signaling stimulated by nuclear-localized PDK1 results in oncogenesis. Sci Signal (2012) 0.83

Constitutive cytoplasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia. Leukemia (2003) 0.82

Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer. Asian Pac J Cancer Prev (2012) 0.76

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood (2010) 7.50

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52

Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med (2016) 5.07

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood (2007) 4.64

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer (2007) 4.60

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood (2005) 3.68

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood (2005) 3.63

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood (2007) 3.18

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol (2013) 2.74

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood (2006) 2.55

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood (2008) 2.16

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood (2006) 2.12

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol (2009) 1.98

Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol (2002) 1.98

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol (2009) 1.98

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol (2009) 1.96

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood (2005) 1.85

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood (2011) 1.81

Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomised controlled trial. Lancet (2002) 1.78

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol (2010) 1.70

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood (2005) 1.70

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol (2010) 1.70

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood (2012) 1.67

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood (2011) 1.62

The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment. Gut (2013) 1.60

Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 1.57

Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program (2009) 1.56

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood (2007) 1.54

Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA (2009) 1.53

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol (2013) 1.52

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol (2009) 1.52

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood (2009) 1.46

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood (2003) 1.46

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol (2010) 1.45

Do reactive oxygen species play a role in myeloid leukemias? Blood (2011) 1.43

Progress in the treatment of acute myeloid leukemia. Cancer (2007) 1.38

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol (2013) 1.38

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood (2013) 1.36

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood (2006) 1.32

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood (2006) 1.30

Independent prognostic variables in acute myeloid leukaemia. Blood Rev (2010) 1.29

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood (2005) 1.23

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood (2010) 1.22

Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood (2009) 1.18

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood (2009) 1.16

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica (2010) 1.09

Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol (2013) 1.08

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget (2012) 1.05

Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol (2006) 1.04

The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res (2008) 1.02

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood (2013) 1.00

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol (2007) 1.00

The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood (2002) 0.99

Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood (2013) 0.99

PErineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trial. BMC Pregnancy Childbirth (2010) 0.98

The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood (2007) 0.97

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood (2011) 0.96

Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol (2011) 0.96

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol (2012) 0.95

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol (2006) 0.95

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist (2007) 0.94

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood (2008) 0.94

Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood (2002) 0.93

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol (2010) 0.93

Acute leukemia in adolescents and young adults. Semin Oncol (2009) 0.91

Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun (2005) 0.90

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. Blood (2005) 0.89

Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol (2006) 0.89